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Abstract
Background: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis
remains unacceptably high (70–90%) in immunocompromised patients. Amphotericin B (AMB), a polyene antibiotic with
broad spectrum antifungal activity appears to be a choice of treatment but is available only as an intravenous formulation;
development of an oral formulation would be beneficial as well as economical.
Methodology: Poly(lactide-co-glycolode) (PLGA) nanoparticles encapsulating AMB (AMB-NPs) were developed for oral
administration. The AMB-NPs were 113620 nm in size with ,70% entrapment efficiency at 30% AMB w/w of polymer. The
in vivo therapeutic efficacy of oral AMB-NPs was evaluated in neutropenic murine models of disseminated and invasive
pulmonary aspergillosis. AMB-NPs exhibited comparable or superior efficacy to that of AmbisomeH or Fungizone
TM
administered parenterally indicating potential of NPs as carrier for oral delivery.
Conclusions: The present investigation describes an efficient way of producing AMB-NPs with higher AMB pay-load and
entrapment efficiency employing DMSO as solvent and ethanol as non-solvent. The developed oral formulation was highly
efficacious in murine models of disseminated aspergillosis as well as an invasive pulmonary aspergillosis, which is refractory
to treatment with IP Fungizone
TMand responds only modestly to AmBisomeH.
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Introduction
The rate of opportunistic fungal pathogens causing life-threat-
ening infections including aspergillosis, candidiasis and cryptococ-
cosis are climbing inexorably, particularly within patients with
cancer, organ transplant recipients, diabetics and the patients with
congenital and acquired immunodeficiencies [1–3]. Invasive
aspergillosis, in particular, is a leading cause of death in profoundly
immunosuppressed patients [4]. Following environmental expo-
sure to Aspergillus conidia, primary infection usually involves the
respiratory tract. In severely immunocompromised patients, it may
involve other organs, such as brain and sinus, or even cause
disseminated infection [5]. Despite advances in the treatment,
morbidity and mortality rate associated with invasive aspergillosis
remains unacceptably high (70–90%) in immunocompromised
patients [6].
AMB, a polyene antibiotic with broad spectrum antifungal
activity, was also the therapy of choice for visceral leishmanisis
[7,8] but due to concerns about toxicity it is no longer the primary
drug of choice for invasive fungal diseases [9]. AMB, due to its
inherent low solubility and intestinal permeability, shows relatively
poor oral bioavailability and hence is conventionally administrated
parenterally as a miceller formulation with deoxycholate (Fungi-
zone
TM). However, conventional AMB therapy has limited effica-
cy in improving survival rate in conditions such as neutropenic
patients with invasive aspergillosis due to a combination of poor
efficacy and multiple toxicities including serious nephrotoxicity,
haemolysis and liver damage as well as nausea and fever [10–11].
In order to improve the therapeutic index of AMB and reduce
its associated toxicity, lipid-based formulations have been
developed for parenteral administration, including (AmbisomeH,
AmphocilH, and AbelcetH). Despite the improvement in thera-
peutic index for lipid formulations of AMB, their use still remains
limited due to higher cost, difficult route of administration and
ongoing concerns about toxicity [9]. Therefore, the development
of new, effective antifungal delivery systems remains an important
intent.
The development of an effective oral formulation of AMB
would have major applications in the treatment of invasive and
disseminated fungal infections and would also dramatically expand
access to the treatment of invasive mycosis and visceral
leishmaniasis. Various formulations have been investigated for
oral delivery of AMB including nanosuspensions and lipid-based
formulations [12–14]. The nanosuspension of AMB exhibited
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parasite burden only by 28.6% as compared to control in the
murine model of visceral leishmaniasis indicating limited in vivo
efficacy of the formulation [12]. The lipid-based oral formulations
of AMB (Cochleates-based and PeceolH-poly(ethylene glycol)-
phospholipids-based) formulations have been found to be effective
in reducing tissue fungal burden in the murine models of
disseminated aspergillosis and candidiasis [13,14]; however, the
formulation are yet to be evaluated in models of invasive
aspergillosis model, which is more refractory to treatment and
difficult to treat. We have recently reported the improved oral
bioavailability and reduced nephrotoxicity of biodegradable
nanoparticles encapsulating AMB in rodents [15]. The present
study highlights further optimization of the formulation and its
efficacy in murine models of disseminated and invasive pulmonary
aspergillosis following oral administration.
Results and Discussion
Preparation and optimization of nanoparticles
The choice of non-solvent. The mean particle size was
clearly dependent on the type of the non-solvent used and followed
the order water.50% ethanol.100% ethanol (Fig. 1A). Ethanol is
presumably a ‘‘poorer’’ solvent for PLGA as compared to water,
and it promotes the precipitation of the polymer more actively
[16,17]. The size distribution was also changed considerably with
the change in the non-solvent composition, where particles made
with 100% ethanol show narrow distribution profile (Fig. 1B).
Since, the volume of DMSO remained constant, no considerable
change was observed in the entrapment efficiency (Fig. 1A).
The addition of a surfactant (VE-TPGS) was necessary for
stabilization of AMB-NPs suspension as aggregation was observed
without use of VE-TPGS. Considering the lowest particle size and
narrow size distribution, 100% ethanol was used as non-solvent for
the subsequent experiments.
The solvent composition (DMSO:Acetone). The particle
characteristics were significantly affected by the composition of
organic solvent. The particle size as well as entrapment efficiency
were decreased (160623 to 93614 nm and 76611 to 6467%,
respectively) as the fraction of DMSO increased in the solvent
mixture (DMSO:acetone, 25:75.50:50.75:25.100:00) with
little change in the size distribution pattern (Fig 2A&B). The
smallest particles were obtained with the use of 100% DMSO as
the solvent. The trend of decrease in particle size with increase in
the DMSO fraction can be explained by the physico-chemical
properties of the solvents and non-solvents used in the
nanoparticles preparation. The property parameters of the
solvents and non-solvents including the polarity, donicity, and
the acceptivity can be quantitatively characterized by solvent
polarity/polarizability, solvent basicity, and solvent acidity values,
respectively. All of the solvents or non-solvents used in the present
study can be classified into three types: (a) type I, strong electron
pair donor (EPD) with high polarity, high basicity, and low acidity;
(b) type II, solvents with medium polarity and low acidity; (c) type
III, solvents with strong electron pair accepter (EPA) with medium
polarity and high acidity. DMSO (type I) is a good electron pair
Figure 1. The effect of non-solvent composition on particle size, entrapment efficiency (A) and particle size distribution (B). PDI,
water: 0.360.1; 50% ethanol 0.160.07; ethanol 0.160.02.
doi:10.1371/journal.pone.0025744.g001
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lone electron pairs [18]. Acetone (type II) is a solvent with no EPD
or EPA activity and having low acidity. Ethanol (type III) is a good
EPA nonsolvent with high acidity. Therefore, a strong EPD-EPA
interaction arises between DMSO and ethanol molecules and thus
DMSO molecules interacts with the ethanol molecules with higher
affinity as compared to acetone molecules, which could lead to
faster diffusion of the DMSO in the ethanol as compared to
acetone and thus smaller particle size [19]. Since AMB has very
good solubility in the DMSO as compared to acetone, there was a
little decrease in the entrapment efficiency with increase in the
DMSO fraction in the solvent mixture (Fig 2A). Considering
smaller particle size, 100% DMSO was used as solvent for further
experiments.
The solvent volume. Four volumes of DMSO (1, 2, 3 and 4
ml) were used to prepare AMB-NPs and its effect on particle size,
size distribution and entrapment efficiency was evaluated. With
increasing solvent volume from 1 to 4 ml, there was a decrease in
particle size (116622 to 86614 nm) and entrapment efficiency
(7169t o5 4 67%) was observed (Fig 3A & B). This trend might be
explained by considering two facts: (i) the number of polymer chains
per unit volume of solvent and (ii) the influence of polymer
concentration on the viscosity. First with the lowest volume of
solvent,therearegreaternumberofpolymerchainsperunitvolume
of solventand as a consequence of the solvent diffusing into the non-
solvent carries out more polymer chains which aggregate and thus
form larger particle. This phenomenon is also favoured by the fact
that increasing polymer concentration increases polymer-polymer
interactions which means that more polymer chains remain
associated during the diffusion process. On the other hand, the
influence of polymer concentration on the viscosity of the organic
phase is also taken into account. On increasing the polymer
concentration, a more viscous organic phase is obtained, which
provides a higher mass transfer resistance; thus the diffusion of
polymer-solvent phase into the external aqueous phase is reduced
and larger NP are formed [19]. In contrast, a diminution in the
polymer concentration (due to increase in the solvent volume)
decreases the viscosity of the organic phase, which increases the
distribution efficiency of the polymer-solvent phase into the non-
solvent leading to formation of smaller particles.
The decrease in AMB entrapment could be due to increase in
solubility of AMB in external phase due to increase in DMSO
volume. Considering the particle size and entrapment efficiency, 3
ml of organic solvent was selected for further studies.
The initial AMB loading. Effect of initial AMB loading on
particle size, size distribution and entrapment efficiency was
Figure 2. The effect of solvent composition (DMSO:acetone) on particle size, entrapment efficiency (A) and particle size distribution
(B). For all the preparations, PDI is 0.160.01.
doi:10.1371/journal.pone.0025744.g002
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of polymer). With increasing initial loading from 10 to 30% w/w,
an increase in the particle size (77610 to 113615 nm) and
entrapment efficiency (6166t o7 1 69) was observed with
widening of the size distribution (Fig. 4A&B). The increase in
the particle size could be due to the increase in the viscosity of the
organic phase with resultant slower diffusion of the solvent into
non-solvent and higher particle size. Above 30% w/w loading, the
precipitation was observed indicating that PLGA could not hold
AMB above this concentration. The formulation with 30% w/w of
AMB loading was selected for the in vivo studies.
Efficacy of AMB-NPs in murine models of pulmonary and
disseminated aspergillosis
Inhalational murine model of invasive pulmonary
aspergillosis. Control mice developed a heavy lung burden
that was associated with weight loss and respiratory distress.
Treatment with 1.5 mg/kg/day FungizoneTM IP, 5 mg/kg/day
AmBisomeH IV, 2.5 mg/kg/day posaconazole oral and the single
dose of 5mg/kg oral AMB-NPs caused numerical reductions in
tissue burden none of which were statistically significant (p.0.05)
(Fig. 5). Treatment with 5 mg/kg AMB-NPs either administered
as single dose IV (p=0.0077) or daily dosing IV (p=0.0009) or
orally caused large statistically significant reductions in lung
burden. Of note AMB-NPs when administered as a single 5 mg/kg
IV dose was superior to 1.5mg/kg/day conventional AMB
(p=0.0156) similarly AMB-NPs 5 mg/kg/day were also superior
regardless of whether the drug was administered orally (p=0.002)
or IV (p=0.0003).
Murine model of disseminated aspergillosis. In this
model control mice developed heavy and reproducible kidney
burdens but remained healthy throughout the experimental
observation period. Treatment with FungizoneTM IP (0.1 or 0.3
mg/kg/day), single oral doses of 2 or 5 mg/kg AMB-NPs, 0.3 mg/
kg/day IV AMB-NPs, and 2.5 mg/kg/day oral posaconazole all
significantly reduced the kidney fungal burden. Numerically
treatment with 0.3 mg/kg/day AMB-NPs was superior to
FungizoneTM but the difference was not statistically significant.
Delmas et al., (2002) reported AMB-Cochleates formulation
with significant anti-fungal activity upon oral administration. The
formulation at the total dose of 560 mg/kg (administered in
divided doses as 40 mg/kg daily for 14 days) caused 2 log
reduction in fungal burdens of lungs, livers and kidneys of the
neutropenic mice infected with A. fumigatus [13]. Considering the
dose and duration of the therapy, the efficacy of the formulation
was only moderate. In present studies, oral AMB-NPs exhibited
better therapeutic efficacy and caused 2.14 logs reduction in lung
fungal burden in invasive model with just 20 mg/kg total dose
Figure 3. The effect of solvent (DMSO) volume on particle size, entrapment efficiency (A) and particle size distribution (B). For all the
preparations, PDI is 0.160.01.
doi:10.1371/journal.pone.0025744.g003
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efficacy was observed in the disseminated model where oral AMB-
NPs caused 1.44 logs reduction in kidney fungal burden following
single oral dose of 5 mg/kg (Fig. 6A).
Risovic et al., (2007) evaluated the anti-fungal efficacy of an oral
lipid based formulation of AMB made with PeceolH in male albino
Sprague-Dawley rats infected with A. fumigatus. Treatment with
Peceol-AMB at the dose of 50 mg/kg/day for 4 days significantly
reduced fungal burdens only in the brain and spleen but had no
effect on fungal burdens in the kidneys, heart, liver or lungs of
treated animals compared to control values [20]. Recently, Wasan
et al., (2009) determined the anti-fungal efficacy of a Peceol/
distearoylphosphatidylethanolamine-poly(ethylene glycol)2000based
oral formulation of AMB in immunosuppressed male albino
Sprague–Dawley rats infected intravenously with the A. fumigatus.
Oral administration of the formulation at a total dose of 40 mg/kg
(administered in 4 divided doses, 10 mg/kg twice a day for 2 days)
resulted in ,95% suppression of kidney fugal burdens compared
to controls [14]. AMB-NPs showed better efficacy and suppressed
kidney fungal burden by .97% following oral treatment at just 5
mg/kg single dose (Fig. 6-Panel B). Overall, oral treatment with
AMB-NPs as either a single or multiple dose exhibited anti-fungal
activity comparable/better to parenteral therapy with Fungizo-
neTM and AmBisomeH. Considering shorter duration of therapy
in the present experiment, the longer dosage regimen (as used in
human) should completely cure the infection. Suitability of AMB-
NPs for intravenous bolus injection presents additional advantage,
offering possibility of alternate dosage form, which could provide
convenience in switching between intravenous and oral formula-
tions.
The IPA model used in the present study is a very severe model
and the therapy with conventional AMB is not very effective at
treating this model. In the present study, the oral and
intravenously administered AMB-NPs were highly effective for
treating the infected animals. The impressive oral efficacy of the
AMB-NPs could be the result of enhanced oral absorption.
Nanoparticles are known to enhance the intestinal uptake of the
encapsulated drugs by various mechanisms including protecting
drug from degradation in harsh gastro-intestinal pH and enzymes,
bypassing first pass metabolism, and increasing the lymphatic
Figure 4. The effect of initial AMB loading on particle size, entrapment efficiency (A) and particle size distribution (B). PDI for 10%
Loading: 0.160.01; 20%: 0.260.00; 30%: 0.260.01.
doi:10.1371/journal.pone.0025744.g004
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attributed to enhanced oral bioavailability. The present experi-
ments illustrate that oral AMB-NPs are effective in treating
disseminated and invasive aspergillosis indicating that NPs are
promising carriers for the oral delivery of AMB.
Materials and Methods
Preparation and optimization of AMB-NPs
AMB-NPs were prepared by adapting a method developed in
our laboratory with appropriate modifications [15]. Briefly, 5 mg
of AMB (Fluorochem Ltd, UK) and 50 mg of PLGA (Resomer RG
50:50 H; inherent viscosity 0.41 dl/g) (Boehringer, Ingelheim,
Germany) were dissolved in a suitable organic solvent (S) either
DMSO (Fisher Scientific Loughborough UK) or mixture of
DMSO and acetone (Fisher Scientific). This phase was then added
to the dispersing phase (10 ml of water or 50% v/v ethanol (Sigma
Aldrich, Poole, UK) or 100% ethanol) under moderate magnetic
stirring. The dispersing phase comprises a liquid in which the
polymer is insoluble-the non-solvent (NS)-containing a surfactant
Vitamin E-TPGS (VE-TPGS), which was a gift sample from
Eastman Chemical Company (Llangefni, UK). The preparation
was then kept overnight in a fume hood under stirring to allow
evaporation of ethanol. The particles were then purified by
ultrafiltration and freeze-dried using 10% w/v of sucrose a as
cryoprotectant. The method was successful at 1 gm batch size with excellent
reproducibility with respect to particle size, entrapment efficiency and most
importantly recovery.
The size of AMB-NPs was determined by dynamic light
scattering (NanoZS, Malvern Instruments, UK) as an average of 5
measurements. The amount of the drug entrapped in AMB-NPs
was determined by dissolving known amount of formulation in
DMSO followed by appropriate dilution with methanol and
analysis was performed by a validated reverse phase high
performance liquid chromatographic (RP-HPLC) method [15].
The nanoparticulate formulation was thoroughly optimized for
particle size and entrapment efficiency by optimization of
composition of non-solvent, composition and volume of organic
solvent and initial AMB loading.
Selection of the ‘non-solvent’. The effect of type of non-
solvent (water, 50% ethanol and 100% ethanol) on particle size,
size distribution and entrapment efficiency was studied. Briefly, 5
mg of PLGA was dissolved in 0.65 ml of DMSO and 50 mg of
PLGA was dissolved in 2 ml of Acetone. The PLGA solution was
then slowly added to the DMSO solution containing AMB under
stirring. The drug-polymer solution was then drop-wise added into
10 ml of non-solvent, either water, 50% ethanol or 100% ethanol
containing 1.4% w/v of VE-TPGS under stirring.
Figure 5. Lung burden of mice with invasive pulmonary aspergillosis treated with AMB-NPs, AMB deoxycholate, AmBisome and
Posaconazole 101 hours post infection (Panel A). Geometric mean tissue burdens (and standard deviations) of mice with invasive pulmonary
aspergillosis treated with AMB-NPs, AMB deoxycholate, AmBisome and Posaconazole 101 hours post infection (Panel B). The p values are from a
Kruskal Wallis test (Conover-Inman).
doi:10.1371/journal.pone.0025744.g005
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The nanoparticles were prepared with various compositions of
organic solvents (DMSO:acetone 25:75, 50:50, 75:25 and 100:00)
and its effect on the particle characteristics studied. All other
parameters (PLGA, 50 mg; AMB, 5 mg; organic solvent, 2 ml of
DMSO; non-solvent, 10 ml of ethanol containing 1 mg/ml of VE-
TPGS) were kept constant.
Effect of solvent volume. The effect of volume of DMSO on
particle size, size distribution and entrapment efficiency was
determined. The volumes studied were 1, 2, 3 and 4 ml of DMSO.
All other parameters (PLGA, 50 mg; AMB, 5 mg; non-solvent, 10
ml of ethanol containing 1 mg/ml of VE-TPGS) were kept
constant.
Effect of initial loading of Amphotericin B. The influence
of initial AMB loading on particle characteristics was studied using
10, 20, 30 and 50% w/w of polymer. All other parameters (PLGA,
50 mg; DMSO volume, 3 ml and non-solvent, 10 ml of ethanol
containing 1 mg/ml of VE-TPGS) were kept constant.
Efficacy of AMB-NPs in murine models of pulmonary and
disseminated aspergillosis
All animal experiments included in this study were part of
ongoing studies performed under UK Home Office project licence
PPL40/3101 and had received ethical clearance from the
University of Manchester Ethics Review Panel. Male CD1 mice
(Charles River Ltd., Kent, United Kingdom) weighing 22 to 25 g
were used. The mice were housed in vented HEPA-filtered cages,
and food and water were provided ad libitum.
Inhalational murine model of invasive pulmonary
aspergillosis
A persistently neutropenic inhalational murine model of
invasive pulmonary aspergillosis was used to examine the in vivo
efficacy of AMB-NPs. Briefly, mice were rendered neutropenic on
day minus 2 and +3 with; cyclophosphamide (Baxter Healthcare
ltd, Norfolk, UK) 200 mg/kg intraperitoneally (IP) and cortisone
acetate (Sigma) 250 mg/kg subcutaneously (SC), which resulted in
profound and persistent neutropenia for 6 days. Mice (n=6 per
cage) were exposed to 12 mL of a suspension containing 8.1 x 108
A. fumigatus A1163 spores/mL, harvested from 7 day old cultures
on Sabouraud glucose agar (Oxoid Basingstoke UK) by flooding
the plate with phosphate buffered saline (Invitrogen, Paisley, UK)
with 0.05% Tween 80 (Sigma), that was nebulized (Hudson RCI,
High Wycombe, UK) at 1 bar for one hour. The desired inoculum
was verified by quantitative culture [24].
AMB-NPs were diluted in saline and administered at 5 mg/kg
both IV and by oral gavage. AMB-NPs were either administered
once 5 hours post treatment or once daily. AMB (FungizoneTM
ER Squibb & Sons Ltd, Hounslow, England) was diluted to the
desired concentration in 5% glucose and was administered IP once
daily at 1.5 mg/kg. AmBisomeH (Gilead Sciences Int, UK) was
diluted in 5% glucose administered once daily IV at 5 mg/kg.
Figure 6. Kidney burden of mice with disseminated aspergillosis treated with AMB-NPs, AMB deoxycholate, and Posaconazole 101
hours post infection (Panel A). Geometric mean tissue burdens (and standard deviations) of mice with disseminated aspergillosis treated with
AMB-NPs, AMB deoxycholate, and Posaconazole 101 hours post infection (Panel B). The p values are from a Kruskal Wallis test (Conover-Inman).
doi:10.1371/journal.pone.0025744.g006
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xypropyl)-b-cyclodextrin (Sigma) and administered at 2.5 mg/kg
once daily by oral gavage. Control mice were administered empty
nanoparticles IV once daily. Therapy was initiated 5-hours post-
exposure and was continued for 4 days (4 doses for most drug).
Mice were euthanized 101 hours post infection and the lungs
cultured quantitatively on Sabouraud dextrose agar.
Murine model of disseminated aspergillosis
A temporarily neutropenic murine model of disseminated
aspergillosis was also used to examine the in vivo efficacy of
AMB-NPs. Briefly, mice were rendered neutropenic on day minus
3 with; cyclophosphamide 200 mg/kg intraperitoneally (i.p.) which
resulted in profound neutropenia for 3 days post infection. Mice
(n=5 per cage) were infected with 8 x 104 A. fumigatus A1163
spores per 25 g mouse on day 0 via the lateral tail vein (3 days post
immunosuppression). The desired inoculum was verified by
quantitative culture [25].
Mice were treated as above 2 and 5 mg/kg AMB-NPs once only
by oral gavage, 0.3 mg/kg AMB-NPs IV once daily, Posaconazole
2.5 mg/kg oral once daily or control (empty nanoparticles) IV
once daily. Therapy was initiated 5-hours post-exposure and was
continued for 4 days (4 doses for all drugs other than AMB-NPs).
Mice were euthanized 101 hours post infection and the kidneys
cultured quantitatively on Sabouraud dextrose agar.
Statistics. In the present studies, normality of the data was first
analysed using Minitab 15 statistical software using Kolmogorov-
Smornov Test. Since the data was found to be non-normally
distributed, Kruskal Wallis test (non-parametric equivalent test of
ANOVA) was applied.
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